Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Loading Events

« All Events

  • This event has passed.

Toronto CLL Support Group

September 13, 2021 @ 7:00 pm - 9:00 pm

|Recurring Event (See all)

An event every 2 months that begins at 7:00 pm on day Second of the month, repeating until November 14, 2022

Toronto CLL Support Group

Take a break and read all about it

CLL Society Ed Forum On Demand: CLL Society and Huntsman 5th Annual Patient & Caregiver Educational Forum

In partnership with Huntsman Cancer Institute (HCI), CLL Society invites you to attend our virtual Ed Forum focused on chronic lymphocytic leukemia (CLL). Featured speakers will present the basics of CLL diagnosis, early management, clinical trials, treatment options, COVID-19 considerations for CLL patients, patient perspectives, and strategies to become an effective self-advocate.

Rewriting the Treatment Script in CLL

Four world-class CLL physicians reviewed the latest research and offered case study examples to illustrate their new approaches to treating CLL. The panel, sponsored by the Peer Review Institute and the CLL Society, was for medical professionals and is quite comprehensive in terms of clinical trial data as well as real-world insights from surveys, etc.

ASH 2021: Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

In this study presented at the American Society of Hematology Annual Meeting and Exhibition (ASH 2021),  the authors evaluated the effectiveness of triple gene-modified cells, called “iDuo” Natural Killer (NK) cells. Dr. Alex Danilov interviews Dr. Veronika Bachanova, MD, Professor of Medicine and Director of Cell Therapies and Hematologic Malignancy Department at the University of Minnesota, to discuss the topic

ASH 2021: Dr. Nitin Jain on First-Line Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Chronic Lymphocytic Leukemia (CLL)

At the American Society of Hematology (ASH) 2021, Dr. Nicole Lamanna, Associate Clinical Professor of Medicine at Columbia University Medical Center, interviewed Dr. Nitin Jain, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. They discussed early results from an ongoing study of a triple combination therapy with venetoclax, obinutuzumab, and atezolizumab, a PD-L1 checkpoint inhibitor.

Dr. Diamond on Building a Better COVID-19 Vaccine for the Immunocompromised

Don Diamond. Ph.D., has been working for decades at City of Hope, Duarte, CA, constructing a new vaccine platform that will benefit the immunocompromised. It’s already been successfully used in post allogeneic hematopoietic stem cell (bone marrow) transplants to prevent a different viral infection, CMV.

Do You Want To Boost Your Business?

drop us a line and keep in touch


September 13, 2021
7:00 pm - 9:00 pm


Toronto CLL Society Support Group
105 Wellness Way
Toronto, Ontario M3N 0B1 Canada
+ Google Map